Influence of lanatoside based on levosimendan on cardiac function in patients with acute heart failure

Abstract

Objective To observe the influence of lanatoside based on levosimendan on cardiac function in patients with acute heart failure (AHF). Methods 70 AHF patients admitted into our hospital from May 2015 to July 2017 were randomly divided into control group and observation group, 35 cases in each group. Two groups took conventional treatment, the control group was given levosimendan, the observation group was given lanatoside on the basis of the control group. The improvement of cardiac function indexes, BNP and NT-ProBNP levels of the two groups were observed. The clinical efficacy and adverse reactions of the two groups were compared. Results After treatment, the levels of cardiac function indexes in the two groups improved, those in the observation group significantly improved compared with pre-treatment (P<0.05), and cardiac function of the observation group was significantly better than that of the control group (P<0.05). After treatment, the BNP and NT-ProBNP levels of the two groups significantly improved (P<0.05), the BNP and NT-ProBNP levels of the observation group were significantly better than those of the control group (P<0.05). The total incidence of adverse reactions in the observation group (11.43%) was significantly lower than that in the control group (31.43%) (P<0.05). The total clinical effective rate of the observation group (94.29%) was significantly higher than that of the control group (77.14%) (P<0.05). Conclusion Lanatoside on the basis of conventional treatment and levosimendan for AHF patients has good effect on patients’ cardiac function, which can significantly improve BNP and NT-ProBNP levels, with good clinical efficacy, less adverse reactions during drug process, and high drug safety, which is worthy of application. Key words: Lanatoside; Levosimendan; Acute heart failure; Cardiac function